
This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.

Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.

Prof. Mullol share his opinion on connection between loss of smell and sleep disorder in patients with CRSwNP.

Explore resources on the importance of partnering with patients to empower them to take an active role in their care.

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Dr Gutiérrez Junquera discusses ESPGHAN guidelines, clinical data, and long-term management strategies for pediatric EoE.

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP

Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.